Kalaris Therapeutics, Inc. (KLRS) stock
KLRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.43−0.03 (-2.05%)
Close on Nov 17, 2026Market cap $34.04MP/E –Yield –
Kalaris Therapeutics cash
Cash and short-term investments held at the end of each period.
Kalaris Therapeutics's cash was $93.50M at Jun 30, 2026. For fiscal 2025 it was $118.00M, down 0.3% from the year before. The highest annual figure on record is $356.32M in fiscal 2020.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $118.00M | -0.3% |
| FY2024 | Dec 31, 2024 | $118.30M | -35.7% |
| FY2023 | Dec 31, 2023 | $183.90M | -21.3% |
| FY2022 | Dec 31, 2022 | $233.80M | -5.8% |
| FY2021 | Dec 31, 2021 | $248.12M | -30.4% |
| FY2020 | Dec 31, 2020 | $356.32M | +182.6% |
| FY2019 | Dec 31, 2019 | $126.08M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $93.50M | +5.7% |
| Q1 FY2026 | Mar 31, 2026 | $104.90M | +3.9% |
| Q4 FY2025 | Dec 31, 2025 | $118.00M | -0.3% |
| Q3 FY2025 | Sep 30, 2025 | $77.00K | -99.9% |
| Q2 FY2025 | Jun 30, 2025 | $88.43M | -31.8% |
| Q1 FY2025 | Mar 31, 2025 | $100.97M | -28.1% |
| Q4 FY2024 | Dec 31, 2024 | $118.30M | -35.7% |
| Q3 FY2024 | Sep 30, 2024 | $121.90M | -42.9% |
| Q2 FY2024 | Jun 30, 2024 | $129.60M | -47.4% |
| Q1 FY2024 | Mar 31, 2024 | $140.50M | -30.7% |
| Q4 FY2023 | Dec 31, 2023 | $183.90M | -21.3% |
| Q3 FY2023 | Sep 30, 2023 | $213.30M | -19.2% |
| Q2 FY2023 | Jun 30, 2023 | $246.50M | +42.7% |
| Q1 FY2023 | Mar 31, 2023 | $202.60M | +0.6% |
| Q4 FY2022 | Dec 31, 2022 | $233.80M | -5.8% |
| Q3 FY2022 | Sep 30, 2022 | $264.10M | -4.3% |
| Q2 FY2022 | Jun 30, 2022 | $172.70M | -44.9% |
| Q1 FY2022 | Mar 31, 2022 | $201.40M | -40.2% |
| Q4 FY2021 | Dec 31, 2021 | $248.12M | -30.4% |
| Q3 FY2021 | Sep 30, 2021 | $275.84M | -27.1% |
| Q2 FY2021 | Jun 30, 2021 | $313.34M | +199.8% |
| Q1 FY2021 | Mar 31, 2021 | $336.99M | +0.0% |
| Q4 FY2020 | Dec 31, 2020 | $356.32M | +182.6% |
| Q3 FY2020 | Sep 30, 2020 | $378.50M | – |
| Q2 FY2020 | Jun 30, 2020 | $104.50M | – |
| Q1 FY2020 | Mar 31, 2020 | $336.90M | – |
| Q4 FY2019 | Dec 31, 2019 | $126.08M | – |
See a number that looks wrong?